Condition: Acute Lymphoblastic Leukemia · Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia · Sponsor: Ottawa Hospital Research Institute
The investigators propose an early phase study defined as a phase I/II trial assessing safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL). The Initial Stage of the study (n=20 participants) will focus on feasibility and safety while the Extended Stage will include all participants enrolled in the study (n=additional 80 participants for a total of 100) and will focus on efficacy and safety outcomes. In the proposed trial, we will administer our CAR-T cell product to these participants as a single infusion. Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
This description comes directly from the study's public registry record.
Natasha Kekre, MD · 613-737-8899 · nkekre@toh.on.ca
Anne Marie Clement · 6137378899 · amclement@ohri.ca
Always discuss trial participation with your own doctor first.
| Vancouver General Hospital | Vancouver, British Columbia, Canada | Recruiting |
| CancerCare Manitoba | Winnipeg, Manitoba, Canada | Not Yet Recruiting |
| The Ottawa Hospital - General Campus | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03765177